Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SAN FRANCISCO, Aug. 15, 2017 -- NGX Bio, Inc., (www.NGXbio.com) the premier marketplace for online DNA sequencing services, announced it has closed a $3 million funding round. The round was led by 180 Degree Capital Corp. (NASDAQ:TURN) and included Third Kind Venture Capital, Lateral Capital, the Band of Angels and the Berkeley Angel Network, as well as other investors.
NGX Bio was founded in 2014 to provide streamlined, on-line access to next-generation sequencing services for clients seeking high quality, rapid and cost-effective sequencing of both human and non-human samples globally. Demand for sequencing services is growing exponentially. NGX Bio’s platform matches the sequencing needs of customers with providers who have available sequencing capacity. Customers are able to purchase a wide range of sequencing services for their samples using NGX Bio’s online ordering tools. NGX Bio offers these services through numerous and deep relationships with its extensive network of sequencing service providers. The ability to offer virtually unlimited sequencing capacity, to finish projects rapidly, and to always stay at the cutting edge of fast-evolving sequencing technologies distinguishes NGX Bio from its competitors and from internal corporate, academic or government sequencing resources.
“We appreciate the support from our investors to fund the next stage of the growth of our business,” said Denis Kourakin, President and Chief Executive Officer of NGX Bio. “Our platform makes completion of sequencing projects simpler and more affordable for all clients and allows them to scale without the need for capital investment. This funding will allow us to continue our relentless focus on delivering high-quality, rapid and cost-effective sequencing solutions for our customers."
About NGX Bio:
NGX Bio is a San Francisco-based company providing streamlined, on-line access to next generation sequencing services for clients seeking high quality, rapid and cost-effective sequencing solutions globally. Founded in 2014 by two professors of Stanford University, NGX Bio offers virtually unlimited sequencing capacity to its customers through its partnerships with numerous sequencing providers.
Contact: Denis Kourakin Phone: +1 (415) 464 6379 e-mail: [email protected]
